Capital Advisors Inc. OK Sells 261 Shares of Eli Lilly and Company (NYSE:LLY)

Capital Advisors Inc. OK lowered its position in Eli Lilly and Company (NYSE:LLY) by 4.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,426 shares of the company’s stock after selling 261 shares during the period. Capital Advisors Inc. OK’s holdings in Eli Lilly and Company were worth $4,189,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of LLY. Certuity LLC boosted its holdings in shares of Eli Lilly and Company by 107.1% in the fourth quarter. Certuity LLC now owns 5,676 shares of the company’s stock worth $4,382,000 after buying an additional 2,935 shares during the last quarter. Indiana Trust & Investment Management Co raised its position in Eli Lilly and Company by 7.7% in the fourth quarter. Indiana Trust & Investment Management Co now owns 12,737 shares of the company’s stock worth $9,833,000 after acquiring an additional 912 shares during the period. Community Financial Services Group LLC raised its position in Eli Lilly and Company by 7.2% in the fourth quarter. Community Financial Services Group LLC now owns 9,771 shares of the company’s stock worth $7,543,000 after acquiring an additional 660 shares during the period. Signet Investment Advisory Group Inc. boosted its stake in shares of Eli Lilly and Company by 0.4% during the 4th quarter. Signet Investment Advisory Group Inc. now owns 3,833 shares of the company’s stock worth $2,959,000 after acquiring an additional 14 shares during the last quarter. Finally, TCV Trust & Wealth Management Inc. grew its position in shares of Eli Lilly and Company by 1.0% during the 4th quarter. TCV Trust & Wealth Management Inc. now owns 23,998 shares of the company’s stock valued at $18,526,000 after acquiring an additional 236 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.9 %

Shares of LLY stock opened at $872.98 on Thursday. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. The stock has a market capitalization of $828.74 billion, a price-to-earnings ratio of 74.55, a price-to-earnings-growth ratio of 1.87 and a beta of 0.42. Eli Lilly and Company has a 12-month low of $711.40 and a 12-month high of $972.53. The stock’s 50-day moving average price is $792.27 and its 200-day moving average price is $843.94.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 86.26% and a net margin of 23.51%. Equities research analysts predict that Eli Lilly and Company will post 23.33 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be given a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, February 14th. This represents a $6.00 annualized dividend and a yield of 0.69%. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s dividend payout ratio (DPR) is 44.41%.

Eli Lilly and Company announced that its board has authorized a share repurchase program on Monday, December 9th that allows the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization allows the company to repurchase up to 2% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s leadership believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on LLY. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Citigroup decreased their price objective on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Sanford C. Bernstein assumed coverage on Eli Lilly and Company in a research report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price objective on the stock. Wells Fargo & Company reduced their target price on shares of Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating for the company in a report on Tuesday, January 28th. Finally, Barclays lowered their price target on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a report on Thursday, October 31st. Four analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $997.50.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.